We stand at the forefront of a pivotal moment in human innovation—where AI and CRISPR gene editing converge to power what can only be described as the 21st century’s biological revolution.  A New Industrial Epoch  Just as coal and steam powered the 19th-century Industrial Revolution and electricity and chemistry fuelled.

Making CRISPR more accessible for scientific innovation   At ERS Genomics, we make CRISPR/Cas9 accessible to innovators. By licensing the foundational IP co-owned by Professor Emmanuelle Charpentier, we enable a broad spectrum of applications outside of direct therapeutic use—from drug discovery to innovation in fields far beyond pharma. One of.

License agreement provides Jumpcode Genomics access to CRISPR gene editing technology to enhance next-generation sequencing capabilities    Dublin, Ireland, and San Diego, CA, 27 March, 2025: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Jumpcode Genomics (‘Jumpcode’), a life science tools company improving and reducing the cost of next-generation.